image credit- shutterstock
Fujifilm Corporation has signed a joint research agreement with the National Cancer Center Japan, a Tokyo-based national institution recognised for its leadership in cancer care and research.
Under this agreement, Fujifilm and the National Cancer Center Japan will collaborate on the development of novel cancer treatment technologies. The research will focus on evaluating the efficacy and targeted delivery of therapeutic agents using Fujifilm’s proprietary cyclic peptides containing unnatural amino acids and antisense nucleic acids designed by the National Cancer Center Research Institute to selectively induce apoptosis in cancer cells.
Fujifilm will develop peptide–nucleic acid conjugate by linking its proprietary cyclic peptides with antisense nucleic acids designed by the National Cancer Center Research Institute. These conjugates will be evaluated for their ability to selectively induce apoptosis in cancer cells as well as their efficiency in delivery and accumulation in target tissues.
By leveraging advanced molecular design technologies and extensive research expertise, Fujifilm aims to contribute to the development of innovative cancer therapies with enhanced precision and efficacy.
